BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics
Bristol Myers Squibb has joined Brandon Capital, a leading Australian life sciences private equity firm, in supporting Pathios Therapeutics’ Series B financing. The $25 million in funding will support UK-based Pathios to progress the development of its …